Combined neutral endopeptidase inhibitors

Area of Science:

• Cardiovascular Pharmacology
• Renal Physiology

Background:

• The renin-angiotensin-aldosterone system (RAAS) is crucial in hypertension and heart failure.
• ACE inhibitors, AT-II blockers, and aldosterone antagonists target RAAS.
• Combined ACE and neutral endopeptidase (NEP) inhibitors show greater potency in reducing blood pressure.

Purpose of the Study:

• To review the efficacy of NEP inhibitors, particularly omapatrilat, in hypertension and heart failure.
• To assess the safety profile of NEP inhibitors, focusing on angioedema incidence.
• To explore the potential of novel NEP inhibitor combinations.

Main Methods:

• PubMed literature search focused on NEP inhibitors and omapatrilat.
• Review of studies on omapatrilat's efficacy in hypertension and heart failure.
• Analysis of angioedema incidence with combined ACE and NEP inhibitors.
• Evaluation of emerging data on NEP inhibitors combined with AT-II blockers.

Main Results:

• NEP inhibitors, including omapatrilat, demonstrate efficacy in treating hypertension and heart failure.
• A significant incidence of angioedema was observed with combined ACE and NEP inhibitors, limiting their widespread adoption.
• Current studies indicate that combinations of NEP inhibitors and AT-II blockers significantly reduce blood pressure.
• These newer combinations have not been associated with angioedema.

Conclusions:

• NEP inhibitors are effective for hypertension and heart failure but were hindered by angioedema risks.
• Combinations of NEP inhibitors with AT-II blockers represent a promising therapeutic strategy.
• Early findings suggest these novel combinations are safe and effective alternatives.